Fezol - 2.5mg

Tablet
Pack Size :   5 Tablet x 1 Strip
Generics :   Letrozole
Manufacturer :   Acme Laboratories Ltd.
Best Price * TK  200.00
* Delivery will be done in Dhaka city only.

More Information About - Fezol - 2.5mg

Description

Generic Name

Letrozole

Precaution

Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery. Lactation: not known if excreted in breast milk (for post-menopausal women)

Indication

Breast cancer

Contra Indication

Premenopausal women and children; hypersensitivity.

Dose

N/A

Side Effect

Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation. Potentially Fatal: Thromboembolic events.

Pregnancy Category

Name : Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Letrozole competitively binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgen to oestrogen, leading to inhibition of the enzyme and a significant reduction in plasma oestrogen levels.

Interaction

Plasma levels reduced by tamoxifen.

Pregnancy Category Note

Pregnancy Based on post-marketing reports, findings from animal studies and mechanism of action, therapy can cause fetal harm and is contraindicated for use in pregnant women; in post-marketing reports, use during pregnancy resulted in cases of spontaneous abortions and congenital birth defects; however, data are insufficient to inform a drug-associated risk Contraception Advise females of reproductive potential to use effective contraception during treatment and for at least 3 weeks after last dose Infertility Therapy may impair fertility in females and males of reproductive potential Lactation Not known if therapy is present in human milk; there are no data on effects on breastfed infant or milk production; exposure of lactating rats to drug was associated with impaired reproductive performance of male offspring; because of potential for serious adverse reactions in breastfed infants, advise lactating women not to breastfeed while receiving therapy and for at least 3 weeks after last dose

Adult Dose

Oral Advanced or locally advanced breast cancer ; Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer Adult: 2.5 mg once daily. Hepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days.

Child Dose

N/A

Renal Dose

N/A

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.

Others Product

In Stock
Prescribed
Tablet Epitra 2mg Clonazepam Square Pharmaceuticals Ltd.
Tk 110
In Stock
Injection Testanon - 250 MG/ML Testosterone Decanoate Nuvista Pharma Ltd
Tk 174.19
In Stock
Tablet Montiva 5 mg Tab Montelukast NIPRO JMI Pharma Limited
Tk 80
In Stock
Tablet Ebaril 10 mg Ebastine Incepta Pharmaceuticals Ltd.
Tk 60